Novo Nordisk experimental obesity pill has mild-to-moderate side effects in early trial
Novo Nordisk's highly anticipated experimental weight-loss pill amycretin was safe and tolerable for patients in an early-stage trial, with mild-to-moderate side effects, the company said on Wednesday.
Novo's older obesity drug is safe and effective for children, study finds
Novo Nordisk's older weight-loss drug Saxenda helped children between the ages of 6 and under 12 reduce their body mass index by 7.4% in a 56-week trial, according to results presented at a medical meeting on Wednesday.
Is Novo Nordisk (NVO) a Buy as Wall Street Analysts Look Optimistic?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Novo Nordisk A/S (NVO) Is a Trending Stock: Facts to Know Before Betting on It
Novo Nordisk (NVO) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Ozempic shortages in EU will not affect all member states - Novo Nordisk
Intermittent shortages of diabetes drug Ozempic in the European Union that are expected to continue into the final quarter of 2024 because of strong demand will not affect all member states, the Danish drugmaker Novo Nordisk said.
Weight-loss drugs could reduce COVID-related deaths: Study
A new study found that weekly injections of 2.4 mg of semaglutide could lower the risk of deaths related to COVID-19, marking another potential benefit of these blockbuster drugs.
Novo Nordisk's Ozempic shortage expected to continue into Q4
Novo Nordisk said the shortage of lower strengths of its diabetes drug Ozempic has deteriorated, with intermittent shortages for all strengths expected into the final quarter of 2024 due to increased demand and along with capacity constraints at some of its manufacturing sites.
These 3 Factors Could Make Eli Lilly Stock a Better Buy Than Novo Nordisk Right Now
Eli Lilly and Novo Nordisk compete in a handful of different markets. Novo Nordisk is scaling up its output and upgrading its medicines a bit more slowly.
This New Finding About Ozempic and Wegovy Could Hurt Novo Nordisk's Stock
Wegovy and Ozempic are based on the same molecule called semaglutide. An investigation into the side effects of semaglutide was just published.
Investors Heavily Search Novo Nordisk A/S (NVO): Here is What You Need to Know
Recently, Zacks.com users have been paying close attention to Novo Nordisk (NVO). This makes it worthwhile to examine what the stock has in store.
We've had "diabesity"; now here's what "pre-diabesity" means for Novo Nordisk, Eli Lily et al
The surge in GLP-1 obesity-related research is highlighting a critical shift in medical literature, according to a recent analysis by Deutsche Bank. It notes that managing obesity is becoming increasingly vital, with terms like "diabesity"—the intersection of diabetes and obesity—gaining traction since 2023.
Ozempic Could Have a Terrible Side Effect. Is Novo Nordisk in Trouble?
A recent study claims that Ozempic is linked with a higher risk of suicidal thoughts than other drugs. However, other studies have reached the opposite conclusion.
